

# Responsibility Statement

The board today consider and approved the condensed, consolidated financial statement for the six months ending 30 June 2018 for BerGenBio.

The half year report has been prepared in accordance with IAS 34 Interim Financial Reporting as endorsed by the EU and additional Norwegian regulation.


We confirm, to the best of our knowledge that the financial statements for the period 1 January to 30

June 2018 have been prepared in accordance with current applicable accounting standards, and give a true and fair view of the assets, liabilities, financial position and profit or loss of the entity and the group taken as a whole.


We also confirm that the Board of Directors' Report includes a true and fair view of the development and performance of the business and the position of the entity and the group, together with a description of the principal risks and uncertainties facing the entity and the group.

Bergen, 20 August 2018

Board of Directors and CEO of BerGenBio ASA




Stein H. Annexstad, Chairman



Susan Foden



Sveinung Hole



Jan Øyvind Eriksen




Hilde Furberg



Kari Grønås



Stener Kvinnsland



Richard Godfrey (CEO)